Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
INDV
$39.01
+2.07%
INDV · Indivior Pharmaceuticals, Inc.
$39.01
+0.79 (+2.07%)
At close · Aug 14
Market Cap
$4.60B
Shares
118.01M
All earnings calls
Earnings call · FY2025 Q4
Indivior Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Indivior Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Forward guidance
2 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Revenue · derived Q4
$357.00M
+19.8% YoY
Gross margin · derived Q4
82.1%
-1.8 pp YoY
Net income · derived Q4
$103.00M
+390.5% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Feb 26, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Total SUBLOCADE Net Revenue
Full-Year 2026
|
$905M – $945M | — | |
|
Adjusted EBITDA
Full-Year 2026
|
$535M – $575M | Non-GAAP |
SEC filing · Item 2.02
8-K earnings release
Filed Feb 26, 2026 · complete as-filed document
SEC periodic report
10-K report
Filed Feb 26, 2026 · complete as-filed document